<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-07T21:03:06Z</responseDate>
  <request identifier="oai:figshare.com:article/34039227" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34039227</identifier>
        <datestamp>2026-10-01T05:31:09Z</datestamp>
        <setSpec>category_696</setSpec>
        <setSpec>portal_316</setSpec>
        <setSpec>item_type_1</setSpec>
        <setSpec>month_year_10_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Image 2_Patient-aware single-cell analysis of fibrovascular remodeling in a predominantly colorectal cancer immunotherapy cohort.tiff</dc:title>
          <dc:creator>Yang Gu (400592)</dc:creator>
          <dc:creator>Li Li (14993)</dc:creator>
          <dc:creator>Yuxian Zhang (6375074)</dc:creator>
          <dc:creator>Jie Tang (46802)</dc:creator>
          <dc:creator>Zhigang Wang (13556)</dc:creator>
          <dc:creator>Xiaofeng Luo (405693)</dc:creator>
          <dc:subject>Genetic Immunology</dc:subject>
          <dc:subject>cancer-associated fibroblast</dc:subject>
          <dc:subject>colorectal cancer</dc:subject>
          <dc:subject>immune checkpoint blockade</dc:subject>
          <dc:subject>pericyte</dc:subject>
          <dc:subject>single-cell RNA sequencing</dc:subject>
          <dc:description>Background&lt;p&gt;Cancer-associated fibroblasts (CAFs) and vascular mural cells may shape extracellular matrix organization in colorectal cancer. However, single-cell comparisons are susceptible to unequal cell recovery, ambient RNA, doublets, treatment-stage mixing, and repeated sampling within patients. We investigated fibrovascular remodeling using patients as the inferential unit and distinguished reproducible signals from donor-concentrated and context-dependent findings.&lt;/p&gt;Methods&lt;p&gt;We reanalyzed a published single-cell RNA sequencing cohort of 22 patients, including 20 with colorectal cancer and 2 with duodenal carcinoma. The primary pericyte analysis included 14 pretreatment matched normal-tumor pairs with at least three pericytes per tissue. We assessed ambient contamination and doublets using DecontX and scDblFinder. CAFs were reclustered at six response-blind resolutions, and the stable parent population was tested by patient-blocked pseudobulk analysis after excluding its dominant donor. Independent CRC single-cell and spatial datasets, a cross-cancer immunotherapy cohort, and TCGA were used for external testing.&lt;/p&gt;Results&lt;p&gt;After DecontX correction, tumor pericytes had higher ECM6 scores (median paired change 0.309; false discovery rate [FDR] 0.018). Scores were also higher for the matrix stiffness transcriptional proxy (0.277; FDR 0.012) and the hypoxia/angiogenesis transcriptional program (0.255; FDR 0.028). All three signatures remained significant at the five-pericyte threshold (n=13). COL1A1 and FN1 increased in the analysis, although COL1A1 was borderline in the five-cell sensitivity analysis. Response-blind stability analysis identified a 2,983-cell ECM-remodeling CAF population represented in all 22 patients. After excluding P02, patient-blocked pseudobulk analysis in 15 patients showed higher matrix, inflammatory, and myCAF-related programs and a lower iCAF program. Neither SPP1 nor baseline enrichment in stable disease was supported. In GSE205506, a disjoint 10-gene fibroblast gate retained higher inflammatory and composite CAF scores in non-pCR samples. The highest-scoring unsupervised cluster was donor-concentrated and showed no patient-level association with response. Spatial and cross-cancer analyses yielded mixed or null results.&lt;/p&gt;Conclusions&lt;p&gt;These results support pretreatment fibrovascular transcriptional remodeling at the patient level. They do not establish an SPP1-high response biomarker, a mechanical stiffness phenotype, or causal CAF-to-pericyte signaling. Donor-aware analysis places the rare-cluster observation within a broader, reproducible ECM-remodeling CAF program while defining its evidential limits.&lt;/p&gt;</dc:description>
          <dc:date>2026-10-01T05:31:09Z</dc:date>
          <dc:type>Image</dc:type>
          <dc:type>Figure</dc:type>
          <dc:identifier>10.3389/fimmu.2026.1961075.s002</dc:identifier>
          <dc:relation>https://figshare.com/articles/figure/Image_2_Patient-aware_single-cell_analysis_of_fibrovascular_remodeling_in_a_predominantly_colorectal_cancer_immunotherapy_cohort_tiff/34039227</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
